Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Erratum

Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine

Authors: Wang Junwei, Zhang Xiumin, Ye Jing, Yang Shoujing, Li Zengshan

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Excerpt

Following publication of the original article [1] it was brought to our attention that the second author name had been misspelt. Please note that the second author name should be “Zhang Xiumin” and not “Zhan Xiumin” as was originally presented. …
Literature
1.
Metadata
Title
Erratum to: In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine
Authors
Wang Junwei
Zhang Xiumin
Ye Jing
Yang Shoujing
Li Zengshan
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0375-5

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary research

MiR–20a-5p promotes radio-resistance by targeting Rab27B in nasopharyngeal cancer cells

Review

An overview of the role of platelets in angiogenesis, apoptosis and autophagy in chronic myeloid leukaemia

Primary Research

Secretory phospholipase-A2 and fatty acid composition in oral reactive lesions: a cross-sectional study

Primary research

miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma

Primary research

Establishment and characterization of a novel highly aggressive gallbladder cancer cell line, TJ-GBC2

Primary Research

ARNT is a potential direct HIF-1 target gene in human Hep3B hepatocellular carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits